- Fortrea (NASDAQ:FTRE) has received a #1 (Strong Buy) rating from Zacks Investment Research, signaling a robust earnings outlook.
- Mizuho Securities has raised its price target for Fortrea to $16.00.
- The company’s stock performance has shown significant movement, with a 52-week range from $4.46 to $18.67, and its second-quarter financial results are anticipated on July 29, 2026.
Fortrea (NASDAQ:FTRE) is a global contract research organization (CRO). The company provides clinical development and patient access solutions to the life sciences industry, helping other firms with drug research and trials. It currently has a market capitalization of approximately $1.68 billion, indicating its size within the sector.
In a recent comparison, Fortrea was evaluated against its peer, argenx SE (NASDAQ:ARGX). As highlighted by Zacks Investment Research, Fortrea holds a #1 (Strong Buy) rating, while argenx SE is rated #3 (Hold). This suggests that analysts believe Fortrea has a stronger earnings outlook than its competitor.
On July 13, 2026, Mizuho Securities raised its price target for Fortrea to $16.00, an increase from the previous target of $13.00. A price target is an analyst’s estimate of a stock’s future value. At the time of the announcement, the stock was trading higher than the new target, at a price of $17.76.
The positive analyst sentiment is supported by recent rating changes. Fortrea was added to the Zacks Rank #1 (Strong Buy) list after its consensus earnings estimate for the current year increased by 31.2% over the last 60 days. Such a significant upward revision in expected earnings often leads to analyst upgrades.
The stock’s price has seen a 52-week range between a low of $4.46 and a high of $18.67. In its most recent trading session, the stock price fluctuated between $17.49 and $18.06, closing with a gain of 0.51% for the day. The company is scheduled to release its second-quarter financial results on July 29, 2026.
